Amgen Inc IR Call Rare Disease Investor Analyst Event Transcript
My name is Julienne, and I will be your conference facilitator today for Amgen's Rare Disease Investor Analyst Call. (Operator Instructions) I would now like to introduce Justin Claeys, Vice President of Investor Relations. Mr. Claeys, you may now begin.
Thank you, Julienne. Good afternoon, and welcome to our Rare Disease Investor Call. Rare Disease is Amgen's fourth and newest pillar of long-term growth and is additive to our opportunities in General Medicine, Oncology and Inflammation. Today, you will hear from Murdo Gordon, Vikram Karnani, Paul Burton and Jay Bradner, who will provide a review of the strategic fit of rare disease with Amgen's capabilities, the growth prospects for key in-line products that are early in their life cycle and the innovative pipeline of mid and late-stage opportunities.
Through the course of the discussion today, we will make some forward-looking statements, which are qualified by our safe harbor statement. And please note that actual results can vary materially.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
